Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Zytiga interaction

The summary of product characteristics for Zytiga (abiraterone acetate; Janssen-Cilag) now states that concomitant use of strong inducers of CYP3A4 (including phenytoin, carbamazepine, rifampicin, rifabutin, rifapentine, phenobarbital and St John’s wort [Hypericum perforatum]) should be avoided.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2014.20065701

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Stockley's Drug Interactions

    Stockley's Drug Interactions

    Now in its twelfth edition, Stockley’s Drug Interactions is still the most comprehensive and authoritative international source of drug interaction information.

    £240.00Buy now

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.